Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to $76.9 million.

  • Iovance Biotherapeutics' Total Non-Current Liabilities was N/A to $76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.9 million, marking a year-over-year change of. This contributed to the annual value of $77.7 million for FY2024, which is 9.07% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Total Non-Current Liabilities stood at $76.9 million for Q3 2025, which was down 3.66% from $79.8 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Total Non-Current Liabilities ranged from a high of $106.6 million in Q1 2024 and a low of $70.6 million during Q1 2023.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $79.8 million (2025), whereas its average is $83.4 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Total Non-Current Liabilities skyrocketed by 50.95% in 2024, and later fell by 28.53% in 2025.
  • Iovance Biotherapeutics' Total Non-Current Liabilities (Quarterly) stood at $85.4 million in 2023, then fell by 9.07% to $77.7 million in 2024, then declined by 28.53% to $76.9 million in 2025.
  • Its last three reported values are $76.9 million in Q3 2025, $79.8 million for Q2 2025, and $76.2 million during Q1 2025.